Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis
Objective To evaluate the efficacy and safety of faricimab compared with other anti-vascular endothelial growth factor (anti-VEGF) agents in treating neovascular age-related macular degeneration (nAMD) patients.Methods and analysis A systematic review (SR) was conducted up to January 2023. Network m...
Saved in:
Main Authors: | Francisco Rodríguez, Daniel Samacá-Samacá, Claudia Hernández-Castillo, Laura Prieto-Pinto, Carolina Sardi, Hugo Ocampo, Joshua Kock, Fabián Hernández |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-05-01
|
Series: | BMJ Open Ophthalmology |
Online Access: | https://bmjophth.bmj.com/content/9/1/e001702.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of optical coherence tomography vs. fluorescein angiography-based macular neovascularization classifications in age-related macular degeneration
by: Gábor G. Deák, et al.
Published: (2025-02-01) -
Zoledronic acid as adjuvant therapy in neovascular age-related macular degeneration: a randomised controlled pilot study
by: Øystein Kalsnes Jørstad, et al.
Published: (2024-12-01) -
Predictive value of different baseline optical coherence tomography biomarkers for visual acuity changes in neovascular age-related macular degeneration
by: Hamid Riazi-Esfahani, et al.
Published: (2025-02-01) -
Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response—a scoping review
by: Nikolaos Dervenis, et al.
Published: (2024-05-01) -
Eligibility for faricimab in a real-world diabetic macular oedema population: a cross-sectional study
by: Helena Norberg, et al.
Published: (2025-02-01)